Explore more price target data and ratings for Biogen Inc. on the Forecasts tab, and track all previous and future analyst recommendations for Biogen Inc. in the dedicated News Flow.Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a r…
Q2 2026 revenue rose 3.4% year-over-year to $2.74B, driven by rare disease and new immunology products, but net income fell due to higher costs and Apellis integration charges. The Apellis deal added SYFOVRE and EMPAVELI. MS revenue declined amid generic competition. Cash reserves dropped, and risk…
Biogen reported second-quarter 2026 results with total revenue of $2.74 billion, up 3% year‑over‑year, and GAAP diluted EPS of $0.66 and non‑GAAP diluted EPS of $3.60. The company highlighted Growth Portfolio revenue of $1.06 billion (24% year‑over‑year growth) and continued commercial momentum fro…
Biotech company Biogen NASDAQ:BIIBwill be reporting results this Wednesday before market hours. Here’s what to look for.Biogen beat analysts’ revenue expectations last quarter, reporting revenues of $2.48 billion, up 1.9% year on year. It was a strong quarter for the company, with a beat of analyst…
Biogen (NASDAQ:BIIB) advances Alzheimer’s care with new dosing regimens and bioequivalent SC lecanemab, promising real‑world stability for most patients, mixed Phase 2 tau results that slowed decline yet missed primary endpoints, and Phase 3 and combo study plans alongside a virtual ataxia care par…
Virtual-first, multidisciplinary care model delivers care for adults living with ataxias, connecting them to expert neurologist options nationwide.CHICAGO, July 16, 2026 /PRNewswire/ -- Synapticure, a leading virtual care company dedicated to improving access and outcomes for patients and caregiver…
TOKYO and CAMBRIDGE, Mass., July 15, 2026 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB), announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application(sBLA) for a once-weekly lecanemab-irmb subcutaneous injection (U.S. brand…
TOKYO and CAMBRIDGE, Mass., July 13, 2026 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB)announced today that new data presented at the Alzheimer's Association International Conference(R)(AAIC(R)) 2026 in London support that the LEQEMBI(R) (lecanemab) subcutaneous autoinjector (SC…
LEQEMBI IQLIK is a first-of-its-kind anti-amyloid treatment worldwide, offering at-home dosingfor initiation and maintenance (approved in the U.S.)U.S. launch of LEQEMBI IQLIK as an initiation dose planned for late August 2026TOKYO and CAMBRIDGE, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Eisai Co…
LEQEMBI IQLIK is a first-of-its-kind anti-amyloid treatment worldwide, offering at-home dosing for initiation and maintenance (approved in the U.S.)U.S. launch of LEQEMBI IQLIK as an initiation dose planned for late August 2026TOKYO and CAMBRIDGE, Mass., July 13, 2026 /PRNewswire/ -- Eisai Co., Ltd…
Biogen (BIIB) shares jumped 5% on Monday after the U.S. Food and Drug Administration approved the first at-home starting dose for its Alzheimer’s treatment, Leqembi.The decision marks a major shift in how patients can begin therapy for early Alzheimer’s disease.What Does The New Approval Mean For P…
